Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 3NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 3

Conditions

Breast Neoplasms 513Neoplasms 381Lymphoma 341Prostatic Neoplasms 291Melanoma 284Carcinoma, Non-Small-Cell Lung 278Precursor Cell Lymphoblastic Leukemia-Lymphoma 264Lung Neoplasms 257Leukemia, Lymphocytic, Chronic, B-Cell 249Leukemia, Myeloid, Acute 236Leukemia 235Lymphoma, Non-Hodgkin 227Colonic Neoplasms 226Ovarian Neoplasms 208Lymphoma, Large B-Cell, Diffuse 208Multiple Myeloma 207Brain Neoplasms 206Colorectal Neoplasms 203Lymphoma, Follicular 201Rectal Neoplasms 194Burkitt Lymphoma 183Neoplasm Metastasis 180Carcinoma, Renal Cell 172Glioblastoma 169Sarcoma 168Lymphoma, Mantle-Cell 166Pancreatic Neoplasms 158Lymphoma, B-Cell, Marginal Zone 145Unspecified Adult Solid Tumor, Protocol Specific 141Hodgkin Disease 141

Interventions

pazopanib 1ixabepilone 1Thalidomide 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Recurrent Uterine Corpus Sarcoma × Clear all
NCT01168232 2019-08-08

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT00025220 2019-07-23

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Completed
60 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡